Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

NCT03305913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Pretreated Metastatic Colorectal Cancer

Interventions

DRUG: TAS 102
DRUG: Regorafenib

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]